Cancer News

The latest in diagnostics and treatment

As a practice dedicated to the constant exploration of effective treatment for cancer, VCI aims to be your source for news on the latest breakthroughs. Please keep this page as a bookmark and check back regularly. Because one of the most important aspects of fighting cancer is knowing all you can.

World Cancer News

Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer (10/23/2017)

Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced non small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 with Keytruda® (pembrolizumab) is superior to standard chemotherapy and significantly improves survival. Lung cancer remains the leading cause of cancer-related deaths worldwide. In …

Continue reading "Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer"

Flu Shot 101 – What You Need to Know (10/19/2017)

Flu season is here again, and besides a fever and runny nose, it can bring about the longtime controversy surrounding vaccines. In order to protect more human lives this year and to clarify some of the most common misconceptions surrounding the flu vaccine, the team at ConsumerSafety.org met with Dr. William Schaffner, an infectious disease …

Continue reading "Flu Shot 101 – What You Need to Know"

FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma (10/18/2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments,” said Richard Pazdur, M.D., director of …

Continue reading "FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma"

Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer (10/17/2017)

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are already standard of care for advanced NSCLC.1   A recently published study has demonstrated that patients with earlier stage III, locally advanced NSCLC may benefit from anther checkpoint inhibitor Imfinzi …

Continue reading "Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer"

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer (10/16/2017)

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients receive the most appropriate personalized care. Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in …

Continue reading "Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer"

Immunotherapy Active Against Triple-Negative Breast Cancer (10/12/2017)

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple Negative Breast Cancer Approximately 12% of breast cancers are triple-negative breast cancers, meaning that they are estrogen-receptor negative (ER-), …

Continue reading "Immunotherapy Active Against Triple-Negative Breast Cancer"

LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations (10/10/2017)

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition that causes up to 3% of all breast cancers. BRCA + breast cancer is particularly …

Continue reading "LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations"

FDA approves new treatment for certain advanced or metastatic breast cancers (10/05/2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine …

Continue reading "FDA approves new treatment for certain advanced or metastatic breast cancers"

FDA Approves Aliqopa for Relapsed Follicular Lymphoma (10/04/2017)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), which is …

Continue reading "FDA Approves Aliqopa for Relapsed Follicular Lymphoma"

New Standard of Care for Treatment of Resectable Gastric Cancer (10/03/2017)

The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.1 Survival in resectable esophago-gastric cancer is poor. Five-year overall survival is around 25% with surgery, and is increased to 36% by …

Continue reading "New Standard of Care for Treatment of Resectable Gastric Cancer"